Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05652907 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
A Phase 2 study, sponsored by Quantum Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05652907: Clinical Trial Phase 2 study, sponsored by Quantum Biopharma.
NCT05652907 is a Phase 2 study that was terminated before completion, run by Quantum Biopharma. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05652907, a Phase 2 study, was terminated before completion, sponsored by Quantum Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
Primary Outcome
Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity score measured by an 11-point numerical pain rating scale (NPRS). NPRS is an 11-point scale from 0 to10 where the higher number indicates worse pain. Averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 28: calculated weekly average from Day 22 to Day 28
Interventions
- DRUG Placebo
- DRUG FSD201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 2 |
Why NCT05652907 stopped before completion
NCT05652907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05652907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05652907 about?
NCT05652907 is a clinical study titled "Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)". This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
What is the current status of trial NCT05652907?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2023-01-19. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT05652907?
The interventions under investigation include: Placebo (DRUG), FSD201 (DRUG).
Who is sponsoring clinical trial NCT05652907?
This trial is sponsored by Quantum Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05652907's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI